E 8001
Alternative Names: E-8001Latest Information Update: 28 Nov 2023
Price :
$50 *
At a glance
- Originator Eisai Co Ltd
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Transplant rejection
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in Transplant-rejection(In volunteers) in Japan (IV, Infusion)
- 18 Aug 2023 Eisai completes the phase I trial in Transplant rejection (In volunteers) in Japan (IV) (NCT04609852)
- 08 Feb 2021 Phase-I clinical trials in Transplant rejection (In volunteers) in Japan (IV) (Eisai pipeline, February 2021) (NCT04609852)